Study of Hydrolyzed Rice Protein Formula on Growth and Health in Infants With Cows Milk Protein Allergy
Led by Société des Produits Nestlé (SPN) · Updated on 2025-12-26
104
Participants Needed
19
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the growth, gastrointestinal tolerance, quality of life, and acceptability of a new hydrolyzed rice protein-based formula in infants diagnosed with cows milk protein allergy CMPA. The study aims to show that infants fed the new Test Formula grow as well as those fed a Control Formula made of extensively hydrolyzed cows milk protein. The trial is a randomized nutritional clinical study involving infants with CMPA.
Participants will receive either the Test Formula hydrolyzed rice protein formula or the Control Formula commercially available extensively hydrolyzed cows milk formula. The study follows the infants for 4 months after enrollment, assessing growth and health-related outcomes during this period.
During the study, infants will be monitored monthly for weight, length, gastrointestinal symptoms, and cows milk allergy-related symptoms. Additional measurements include head circumference, tibia and femur length, stool frequency and consistency, quality of life assessments, formula compliance, and safety monitoring for adverse events. The primary outcome measure is the weight-for-age z-score at 4 months post-enrollment.
CONDITIONS
Brief Title
Effect of a Hydrolyzed Rice Protein-based Formula on Growth, Tolerance, and Health-related Quality of Life in Infants With Cow's Milk Protein Allergy.
Research Team
A
Anthony de COZAR
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Written informed consent from at least one parent or legal representative
Infant born at or after 37 completed weeks of gestation
Infant birth weight between 2.5 kg and 4.5 kg
Singleton birth
Infant age 8 months or younger
Mother has decided to fully formula-feed; infant is not breastfeeding or receiving breast milk
Suspected cow's milk protein allergy with at least 2 symptoms or diagnosed by tests with at least 1 symptom
Infant on a strict cow's milk elimination diet throughout the study
Parent or legal representative is of legal age, has parental authority, understands consent, and can follow study protocol
You will not qualify if you...
History of intolerance to extensively hydrolyzed formula
Chronic medical diseases (except atopic eczema), chromosomal or major congenital anomalies
Major gastrointestinal diseases other than cow's milk protein allergy
Known or suspected lactose intolerance or malabsorption
Known or suspected soy allergy
Glucose-galactose malabsorption
Rice protein allergy or intolerance
Immunodeficiency
Persistent wheeze or chronic respiratory disease
Severe uncontrolled eczema
History of severe anaphylactic reaction to cow's milk or breast milk requiring 2 or more epinephrine doses
Weight-for-age or height-for-age outside -2 to +2 standard deviations of WHO child growth standards at enrollment
Parent has medical or psychiatric conditions making infant unsuitable
Participation in another interventional clinical study within 4 weeks before enrollment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 4 months
Participants receive either a hydrolyzed rice protein formula or a commercially available extensively hydrolyzed cow's milk formula and are monitored for growth, tolerance, and health-related quality of life.
Monthly visits during treatment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Growth and safety of infants with cow's milk allergy receiving a new hydrolyzed rice protein-based formula containing 2-fucosyllactose and lacto-N-neotetraose: protocol for a randomized clinical trial. The RIGHT-GO study.
Boutaina Zemrani, Nicholas P Hays, Noura Darwish...